Quantcast
Last updated on April 18, 2014 at 6:54 EDT

Latest Ulcerative colitis Stories

2013-07-30 23:27:09

Achieve Clinical Research is conducting a randomized clinical study to evaluate the safety, tolerability, and efficacy of a new drug in subjects with moderate to severe Ulcerative Colitis Birmingham, Alabama (PRWEB) July 30, 2013 *To see if you qualify for this Ulcerative Colitis Clinical Trial in Alabama, visit Achieve Clinical Research on the web (http://www.achieveclinical.com) or contact us directly at (205) 380-6434. There is no cost to participate, no insurance is required, and you...

2013-07-24 08:30:18

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, July 24, 2013 /PRNewswire/ -- Today, Investors' Reports announced new research reports highlighting Biogen Idec Inc. (NASDAQ: BIIB), Illumina, Inc. (NASDAQ: ILMN), Santarus, Inc. (NASDAQ: SNTS), Celsion Corporation (NASDAQ: CLSN), and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and...

2013-07-10 12:28:27

Nature Paper by Team at RIKEN and Vedanta Shows Efficacy of Candidate in Autoimmune Diseases BOSTON, July 10, 2013 /PRNewswire/ -- Scientists have described one of the first instances of a rationally designed drug candidate derived from the human microbiota. The work was led by Dr. Kenya Honda, Team Leader of the Laboratory for Intestinal Homeostasis at the RIKEN Center for Integrative Medical Sciences (IMS) and scientific co-founder of Vedanta Biosciences. The paper describing the...

2013-07-03 11:07:47

A new study indicates that aerobic exercise can lessen – or worsen – the symptoms of inflammatory bowel diseases such as ulcerative colitis, depending on the circumstances under which the exercise is undertaken. The researchers found that, in contrast to their sedentary peers, mice allowed to run freely on an exercise wheel for six weeks had fewer symptoms of colitis after exposure to a chemical agent that induces colitis symptoms in mice. However, mice...

2013-06-28 08:23:36

PRINCETON, N.J., June 28, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today that it has enrolled and treated all patients in the Phase 1 Study BDP-PCD-01; the first clinical study for development of SGX203 (oral beclomethasone 17,21-dipropionate or oral BDP) for...

2013-06-25 19:10:06

Researchers from UH Rainbow Babies & Children's Hospital report reasons behind the increase are unclear The largest investigation to date has found a dramatic increase in the number of hospitalizations for children with inflammatory bowel disease (IBD) during the past decade in the United States. The new study, published online and scheduled for the August 2013 print issue of the Journal of Investigative Medicine, found a 65 percent increase in IBD hospital discharges from 2000 to...

2013-06-21 23:04:27

Bridgestone Retail Operations Customer Round-Up Campaign Supports the Crohn’s & Colitis Foundation of America Bala Cynwyd, PA (PRWEB) June 21, 2013 The Crohn’s & Colitis Foundation of America (CCFA) is delighted to announce that for the months of July and August, Bridgestone Retail Operations, LLC (BRSO) will raise money for Crohn’s disease and ulcerative colitis with a nationwide “round-up” program. BSRO employees and its 2,200 retail locations nationwide, including...

2013-06-21 08:24:56

DEERFIELD, Ill. and OSAKA, Japan, June 21, 2013 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that a Biologics License Application (BLA) has been submitted to the United States (U.S.) Food and Drug Administration (FDA) for vedolizumab, an investigational humanized monoclonal antibody for the treatment of adults with moderately to severely active Crohn's disease (CD) and ulcerative...

2013-06-14 23:04:28

Run Takes Place on August 18th--Sign-up Today (PRWEB) June 14, 2013 Attention: Assignment Editors/Event Producers June 13, 2013              WHAT:             Philadelphia/Delaware Valley Chapter of the Crohn´s &     Colitis Foundation´s 20th annual Guts & Glory 5K Run...

2013-06-05 08:28:50

The role of gut bacteria in ulcerative colitis to be the focus of pharmaceutical collaboration in microbiome R&D SAN BRUNO, Calif., June 5, 2013 /PRNewswire/ -- Second Genome, Inc. announced today that the company has entered into an agreement with Janssen Biotech, Inc. (Janssen) focused on microbiome drug discovery. With the goal of advancing novel drug targets, the agreement is focused on therapeutic mechanisms in ulcerative colitis mediated by the bacterial ecosystem living...